Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Biotech

Biotech

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Biotech
  • Earnings
  • General
  • Guidance
  • Health Care
  • Large Cap
  • Movers
  • News
  • Pre-Market Outlook
  • Trading Ideas

Pfizer’s Q3 Earnings Surpasses Estimates, Lifts Forecasts For COVID-19 Vaccine Sales By $2B

By Vandana Singh
November 1, 8:54 AM
Pfizer Inc (NYSE:PFE) has reported a Q3 adjusted EPS of $1.78, up 40% Y/Y, well ahead of the consensus of…

PFE

Read More
1 minute read
  • FDA
  • News

Processa Says Successfully Identifies Next Generation Capecitabine Dosage Regimens For Phase 2B Trial

By Benzinga Newsdesk
November 1, 8:30 AM
Next Generation Capecitabine (NGC) Dosage Regimens Have Been Identified In The Ongoing Phase

PCSA

Read More
1 minute read
  • FDA
  • News

Harmony Biosciences Announces Topline Results From Phase 2 Proof-of-concept Study Evaluating Pitolisant For Excessive Daytime Sleepiness In Patients With Prader-Willii Syndrome

By Benzinga Newsdesk
November 1, 7:25 AM
Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today

HRMY

Read More
1 minute read
  • Biotech
  • General
  • News

Xeris Biopharma Announces Results Of The Extended Evaluation Of Recorlev From The Phase 3 Sonics Study Published In The European Journal Of Endocrinology

By Benzinga Newsdesk
November 1, 7:15 AM
First prospective long-term levoketoconazole study demonstrating a sustained effect on cortisol levels, as well as improvements in biomarkers of Cushing's syndrome (CS) comorbidity, clinical signs and symptoms

XERS

Read More
1 minute read
  • FDA
  • News

Vigil Neuroscience Receives FDA Fast Track Designation For VGL101 For The Treatment Of Patients With ALSP

By Benzinga Newsdesk
November 1, 7:13 AM
Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that the U.S. Food and

VIGL

Read More
1 minute read
  • Biotech
  • General

Karyopharm And Menarini Group Announce Orphan Medicinal Product Designation From The European Commission For Selinexor For The Treatment Of Myelofibrosis

By Benzinga Newsdesk
November 1, 7:11 AM
Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group ("Menarini"), a privately-held, leading international

KPTI

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • News

UNITY Biotechnology Announces 24-Week Data From Phase 2 BEHOLD Study Of UBX1325 In Patients With Diabetic Macular Edema

By Benzinga Newsdesk
November 1, 7:01 AM
A single injection of UBX1325 led to a statistically significant and clinically relevant improvement in Best Corrected Visual Acuity (BCVA) of 7.6 ETDRS letters at 24 weeks compared to sham treatment   UBX1325

UBX

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • News

FDA Says There Is A Shortage Of Tracheostomy Tubes, Including Bivona Tracheostomy Tubes Manufactured By ICU Medical

By Benzinga Newsdesk
October 31, 3:09 PM
- Reuters

ICUI

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Penny Stocks
  • Price Target
  • Reiteration
  • Trading Ideas

Analysts Slash Y-mAbs Therapeutics Price Targets As Uncertainty Looms Over Neuroblastoma Hopeful

By Vandana Singh
October 31, 3:01 PM
On Friday, FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 16 to 0 that Y-mAbs Therapeutics Inc (NASDAQ:YMAB) did not provide…

YMAB

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Trading Ideas

Hoth Therapeutics’ Atopic Dermatitis Candidate Shows Improvement In Severity, Shares Jump

By Vandana Singh
October 31, 11:39 AM
Hoth Therapeutics Inc (NASDAQ: HOTH) announced Phase 1b trial data for BioLexa in adult patients with mild-to-moderate atopic dermatitis.

HOTH

Posts pagination

Previous 1 … 642 643 644 … 795 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service